Understanding causes of death among men with prostate cancer recurrence after localized treatment is essential for informed decision-making.

These changes are meant to limit the use of the shots while experts collect more data on how well they work for healthy people.

Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs), whether defined as lack of hemoglobin response to typical ESA doses or need for higher ESA doses to reach hemoglobi ...

The programmed death receptor-1-blocking antibody is approved as a single agent or in combination with chemotherapy.

New research suggests that outpatients with cancer are more likely than other outpatients to have antimicrobial-resistant bacterial pathogens.

Deleterious effect of lipoprotein(a) ≥180 nmol/L possibly mitigated by high-impact LDL-cholesterol-lowering therapy.